U.S. Markets closed

NeurAegis Presents Exciting Results for Treating Traumatic Brain Injury

Possible Treatment for Traumatic Brain Injury within 4 Hours of Insult

POMONA, CA / ACCESSWIRE / May 3, 2016 / Traumatic Brain Injury is a significant public health problem globally, affecting 10 million people annually and primary cause of injury-related deaths among young and older individuals. While there has been significant progress made in the understanding of the mechanisms underlying brain injury, most drug trials fail to demonstrate clinical efficacy.

NeurAegis is presenting results using its selective calpain-2 inhibitor, NA 101, on a mouse model of traumatic brain injury ("TBI") at the 6th Annual Traumatic Brain Injury Conference to be held in Washington, DC, May 11-12, 2016.

This conference brings together researchers and clinicians from industry, academia, military and government to discuss recent advances in diagnosis, treatment and long-term care of TBI patients. NeurAegis scientists have identified a critical enzyme, calpain-2, which activates early following brain trauma and is a major contributor to neuronal death. Moreover, NeurAegis scientists have also identified a selective calpain-2 inhibitor, NA 101, and NeurAegis CEO, Dr. Michel Baudry, will present the results obtained with NA 101 in a mouse model of TBI. NeurAegis NA 101 provides an unprecedented degree of neuroprotection when administered within one hour of brain trauma, and is still significantly neuroprotective if given within 4 hours of the trauma.

These results suggest it might be possible to protect soldiers, trauma patients and athletes from the debilitative effects of traumatic brain injury, if NA 101 or a similar molecule can be administered shortly after the injury. The company is currently pursuing the preclinical studies to bring a selective calpain-2 inhibitor to the clinic for the treatment of TBI or related acute trauma in the next 2-3 years.

NeurAegis was founded to translate fundamental discoveries on the mechanisms of synaptic plasticity and neuronal survival/cell death into clinical applications. These discoveries are the results of over 30 years of research by the scientific co-founders, Michel Baudry, PhD, Dean of the Graduate College of Biomedical Sciences, Western University of Health Sciences and Xiaoning Bi, MD, PhD, Professor, College of Medicine, Western University of Health Sciences, directed at understanding the roles of selective biochemical cascades in both synaptic plasticity and neuroprotection/neurodegeneration.

NeurAegis has identified neuroprotection as a key focus for research and development, because of the high unmet needs and tremendous research potential in this therapeutic area. Much work has been conducted to identify the mechanisms underlying neuronal death and significant progress has been made over the last 10-20 years. Nevertheless, there is still no drug on the market that provides any significant degree of neuroprotection, especially within the crucial minutes to maximum of several hours following any brain insult that results in neuronal loss.

Contact information:

Michel Baudry, CEO,
NeurAegis, Inc.

For Further Information:


SOURCE: NeurAegis, Inc.